Bausch + Lomb stock drops 10% following sudden CEO departure, despite raising full-year 2026 EBITDA

Bausch + Lomb Corporation (NYSE: BLCO - Get Free Report)'s stock price fell 5.8% during mid-day trad

Preliminary Update on 2026 Guidance2Based on preliminary third-quarter results, Bausch + Lomb and Ba

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye

Terumo (OTCMKTS:TRUMY - Get Free Report) and Bausch + Lomb (NYSE: BLCO - Get Free Report) are both h

Merit Medical Systems (NASDAQ: MMSI - Get Free Report) and Bausch + Lomb (NYSE: BLCO - Get Free Repo

Activist firm Jana Partners calls for leadership overhaul and asset sales at Cooper Companies (COO)

Bausch + Lomb gains European CE Mark approval for SeeLyra, expanding its surgical portfolio with a c

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye

Leerink Partners analyst Daniel Clark initiates coverage on Bausch & Lomb (NYSE:BLCO) with a

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye

HC Wainwright & Co. analyst Yi Chen reiterates Bausch & Lomb (NYSE:BLCO) with a Buy and m

BLCO advances two eye-health candidates after positive trial results, with combined estimated peak s

Bausch + Lomb (NYSE: BLCO) advances two first-in-class eye drugs to advanced clinical testing, eyein

Bausch + Lomb Corporation (BLCO) Discusses Results and Development Plans for Dual Action Dry Eye Med

Bausch + Lomb NYSE: BLCO said it plans to advance a dual-action dry eye treatment into Phase III dev

Carl Icahn made no new stock purchases in Q2, trimming stakes in JetBlue and American Electric Power

Liquidation represents 54% of insider's direct equity stake, executed at $16.78 per share following

LAVAL, QC, Aug. 6, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC) ("Bausch

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye

HC Wainwright & Co. analyst Yi Chen maintains Bausch & Lomb (NYSE:BLCO) with a Buy and ra

UBS analyst Patrick Wood maintains Bausch & Lomb (NYSE:BLCO) with a Buy and raises the price

Bausch + Lomb Corporation (BLCO) Q2 2026 Earnings Call Transcript

Bausch + Lomb NYSE: BLCO reported second-quarter 2026 revenue growth across its vision care, surgica

Bausch + Lomb (BLCO) came out with quarterly earnings of $0.16 per share, in line with the Zacks Con

Bausch & Lomb (NYSE:BLCO) reported quarterly earnings of $0.16 per share which beat the analyst

Bausch & Lomb (NYSE:BLCO) raises FY2026 sales outlook from $5.420 billion-$5.520 billion to $5.4

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye

UBS analyst Patrick Wood initiates coverage on Bausch & Lomb (NYSE:BLCO) with a Buy rating an

EyeGility is designed for the enVista® family of IOLsOffers balanced push force for smooth delivery,

Bausch + Lomb ended BL1107 glaucoma eye drop development after a Phase 2 miss and will focus on a su

Phase 2 study did not meet its primary endpoint.Company will discontinue development of eye drops fo

Designed to reduce the operational burden that stands between physicians and their patients.Initial

Evercore ISI Group analyst Vijay Kumar maintains Bausch & Lomb (NYSE:BLCO) with a In-Line and

Evercore ISI Group analyst Vijay Kumar maintains Bausch & Lomb (NYSE:BLCO) with a In-Line and

Bausch & Lomb (NYSE:BLCO) raises FY2026 sales outlook from $5.375 billion-$5.475 billion to $5.4

Bausch & Lomb (NYSE:BLCO) reported quarterly earnings of $0.08 per share which beat the analyst

enVista Envy is the first diffractive premium IOL from Bausch + Lomb available in EuropeOffers a con

Evercore ISI Group analyst Vijay Kumar maintains Bausch & Lomb (NYSE:BLCO) with a In-Line and

Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping peopl

In the prospective, multicenter study, investigators at 20 sites across the U.S. enrolled 318 patien

HC Wainwright & Co. analyst Yi Chen maintains Bausch & Lomb (NYSE:BLCO) with a Buy and ra

Barclays analyst Matt Miksic maintains Bausch & Lomb (NYSE:BLCO) with a Equal-Weight and rais

Stifel analyst Tom Stephan maintains Bausch & Lomb (NYSE:BLCO) with a Hold and raises the pri